ClinicalTrials.gov
public full text
Public Domain
Pharmacogenomic Testing in Major Depressive Disorder
This is a two-arm double-blind prospective randomized controlled trial (RCT) to evaluate clinical impact of pharmacogenomic testing on the treatment of major depressive disorder. Participants will be randomly assigned to two groups: pharmacogenomic-guided therapy group (guided group) and treatment as usual group (TAU group). The primary hypothesis is the pharmacogenomic-guided treatment group will demonstrate significantly higher percent improvement in depression score compared to treatment-as-usual group.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phenotype Depression Study#843158
- Mental Health Mission Mood Disorder Cohort Study#1044277
- Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies#7272
- Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis#902947
- Heart Rate Metrics as Potential Biomarkers for Predicting Transcranial Magnetic Stimulation Treatment Response in Treatment-Resistant Depression#231419
Record · ID 1113855
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive